AN2 Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel small-molecule therapeutics derived from its boron chemistry platform. Its pipeline includes epetraborole (targeting polycythemia vera and M. abscessus lung disease), AN2-502998 (targeting Chagas disease), and preclinical oncology programs targeting PI3K and ENPP1. The company also pursues global health programs in melioidosis and tuberculosis, funded primarily through non-dilutive grants.
Q2 FY2026 — expected 2026-08-12
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-17 | 2025-12-31 | 0001193125-26-110693 | EDGAR | 79K words |
| 2025-03-25 | 2024-12-31 | 0000950170-25-044366 | EDGAR | 80K words |
| 2024-03-29 | 2023-12-31 | 0000950170-24-038681 | EDGAR | 85K words |
| 2023-03-29 | 2022-12-31 | 0000950170-23-010627 | EDGAR | 101K words |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-11 | 2026-06-30 | 0001193125-26-344569 | EDGAR | 61K words |
| 2025-11-12 | 2025-09-30 | 0001193125-25-277673 | EDGAR | 60K words |
| 2025-08-12 | 2025-06-30 | 0000950170-25-107301 | EDGAR | 60K words |
| 2025-05-13 | 2025-03-31 | 0000950170-25-070358 | EDGAR | 56K words |
| 2024-11-13 | 2024-09-30 | 0000950170-24-126282 | EDGAR | 58K words |
| 2024-08-13 | 2024-06-30 | 0000950170-24-096243 | EDGAR | 56K words |
| 2024-05-14 | 2024-03-31 | 0000950170-24-059556 | EDGAR | 59K words |
| 2023-11-09 | 2023-09-30 | 0000950170-23-062081 | EDGAR | 64K words |
| 2023-08-10 | 2023-06-30 | 0000950170-23-041378 | EDGAR | 62K words |
| 2023-05-11 | 2023-03-31 | 0000950170-23-021291 | EDGAR | 60K words |
| 2022-11-09 | 2022-09-30 | 0000950170-22-023901 | EDGAR | 64K words |
| 2022-08-11 | 2022-06-30 | 0000950170-22-016900 | EDGAR | 62K words |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-11 | 0001193125-26-344549 | EDGAR | 3K words |
| 2026-03-20 | 0001193125-26-117765 | EDGAR | 1K words |
| 2026-03-17 | 0001193125-26-110681 | EDGAR | 3K words |
| 2026-03-10 | 0001193125-26-099169 | EDGAR | 0K words |
| 2026-01-29 | 0001193125-26-029540 | EDGAR | 1K words |
| 2025-11-12 | 0001193125-25-277662 | EDGAR | 3K words |
| 2025-08-12 | 0000950170-25-107278 | EDGAR | 3K words |
| 2025-06-20 | 0001193125-25-143187 | EDGAR | 10K words |
| 2025-06-11 | 0001193125-25-138796 | EDGAR | 4K words |
| 2025-05-27 | 0001193125-25-127595 | EDGAR | 1K words |
62 total filings indexed. 36 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001880438 |
| Ticker | ANTX |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.an2therapeutics.com |
| Listed | 2022-03-25 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/ANTX (~200 tokens, structured JSON with cryptographic provenance)